When should follow‑up visits be scheduled and when can antiretroviral therapy be initiated in a patient with CMV retinitis receiving valganciclovir?

Follow-up Schedule and ARV Initiation in CMV Retinitis

Start antiretroviral therapy (ART) immediately in patients with CMV retinitis receiving valganciclovir, and schedule ophthalmologic follow-up after completion of induction therapy, at 1 month, then monthly while on anti-CMV treatment.

Timing of ART Initiation

Initiate ART without delay in patients with acute CMV retinitis. The evidence clearly supports starting appropriate antiretroviral therapy immediately in treatment-naïve patients with CMV retinitis, gastrointestinal disease, or pneumonitis 1. No data demonstrate that starting ART among treatment-naïve patients with CMV retinitis would have an adverse effect on retinitis outcomes 1.

Key Rationale:

• Anti-CMV therapy decreases mortality among patients with CMV retinitis and immune compromise 1
• ART takes 3-6 months to fully control HIV replication and stimulate sufficient immune recovery to control retinitis 1
• Even with small peripheral lesions, systemic anti-CMV therapy such as valganciclovir for the initial 3-6 months until ART has induced immune recovery will likely be beneficial 1

Important Exception:

For CMV neurologic disease only, consider delaying ART initiation until clinical improvement occurs due to potential localized morbidity from immune reconstitution inflammatory syndrome (IRIS) 1. This does NOT apply to CMV retinitis.

Ophthalmologic Follow-up Schedule

Perform indirect ophthalmoscopy through a dilated pupil at these specific intervals 1:

1. At diagnosis - baseline documentation
2. After completion of induction therapy (typically 14-21 days)
3. 1 month after initiation of therapy
4. Monthly thereafter while the patient is on anti-CMV treatment

Enhanced Monitoring:

• Monthly fundus photographs using standardized photographic technique provide the optimal method for following patients and detecting early relapse 1
• The FDA drug label specifies ophthalmologic follow-up examinations at a minimum of every 4 to 6 weeks while being treated with valganciclovir tablets, with some patients requiring more frequent follow-up 2

After Immune Recovery:

Once immune recovery is achieved (sustained CD4+ count elevation), the frequency of ophthalmologic follow-up can be decreased to every 3 months 1. However, relapse may still occur, so continued monitoring remains necessary.

Laboratory Monitoring During Valganciclovir Therapy

Monitor complete blood counts, platelet counts, serum electrolytes, and renal function 1:

• Twice weekly during induction therapy
• Once weekly thereafter during maintenance

This is critical because valganciclovir can cause granulocytopenia (neutropenia), anemia, thrombocytopenia, and elevated creatinine levels requiring dose modification or discontinuation 2.

Common Pitfalls to Avoid

1. Do NOT delay ART initiation waiting for retinitis to improve - this increases mortality risk
2. Do NOT confuse CMV retinitis with CMV neurologic disease - the timing recommendations differ
3. Do NOT skip the 1-month ophthalmologic exam - this is when early treatment response is assessed
4. Do NOT reduce monitoring frequency prematurely - maintain monthly exams until immune recovery is documented

IRIS Monitoring

Be vigilant for immune recovery uveitis (IRU), which typically occurs in the first 4-12 weeks after ART initiation among patients with substantial CD4+ count rises 1. This can cause vision loss through macular edema and epiretinal membrane formation.